Last reviewed · How we verify
Placebo (for Aspirin 300) — Competitive Intelligence Brief
phase 3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo (for Aspirin 300) (Placebo (for Aspirin 300)) — Assistance Publique - Hôpitaux de Paris. Placebo has no active pharmacological mechanism; it serves as an inert control in clinical trials to establish baseline efficacy and safety of the active comparator (Aspirin 300).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo (for Aspirin 300) TARGET | Placebo (for Aspirin 300) | Assistance Publique - Hôpitaux de Paris | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo (for Aspirin 300) CI watch — RSS
- Placebo (for Aspirin 300) CI watch — Atom
- Placebo (for Aspirin 300) CI watch — JSON
- Placebo (for Aspirin 300) alone — RSS
Cite this brief
Drug Landscape (2026). Placebo (for Aspirin 300) — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-aspirin-300. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab